Albumin Versus Balanced Crystalloid for the Early Resuscitation of Sepsis: An Open Parallel-Group Randomized Feasibility Trial- The ABC-Sepsis Trial
Alasdair J Gray,Katherine Oatey,Julia Grahamslaw,Sîan Irvine,John Cafferkey,Titouan Kennel,John Norrie,Tim Walsh,Nazir Lone,Daniel Horner,Andy Appelboam,Peter Hall,Richard J E Skipworth,Derek Bell,Kevin Rooney,Manu Shankar-Hari,Alasdair R Corfield,Albumin, Balanced, and Crystalloid-Sepsis (ABC-Sepsis) Investigators,Virginia Newcombe,Robert Chapman,Corinne Hutton,Gavin Perkins,Anthony Gordon,Liza Keating,Philip Pallmann,Ruth Armstrong,Roz Pollock,Tony Wackett,Corrine Hutton,Jane Kale,Neville Kale,Rory Anderson,David Birrell,Polly Black,Caroline Blackstock,Jonathan Carter,Donna Clark,Craig Davidson,Carlyn Davie,Nicola Di Rollo,Andrew Ferguson,Nicholas Fethers,Nicola Freeman,Louise Gibson,Alison Grant,Marie-Clare Harris,Ed James,Katy Letham,Stephen Lynch,Fiona McCurrach,Suzi McKenzie,Connor McLaughlin,Anna Miell,Lyle Moncur,Rachel O'Brien,Gillian Pickering,Matt Reed,Roozbeh Rezai,Sara Robinson,Janet Skinner,Craig Walker,Alison Williams,Emma-Beth Wilson,Jennifer Carruthers,Claire Cheyne,Angela McGeough,Rebecca Lidstone-Scott,Lynn Abel,Santosh Bongale,Susie Currie,Donna Kane,Rachel Keen,Izabella Orlikowska,Natalie Rodden,Jennifer Tait,Nicola Thomson,Lauren Walker,Kate Smith,Ammani Brown,Susanne Cathcart,Donogh Maguire,Patrick O'Mailley,Dominic Rimmer,Catherine Ward,Nicola Baxter,Fraser Denny,Kayleigh Doran,Lisa Dunlop,Jessica Dunn,Lisa Finnen,Darren Green,Emma Hughes,David Lowe,Courtney McArthur,Barbara McLaren,Kirsty McLeish,Linda McMunigal,Chris McParland,Ornagh O'Shaughnessy,Mark Wilson,Roland Armes,Craig Brown,Jamie Cooper,David Connor,Otto Collier-Wakefield,Mandi Coutts,Mairi Cruickshank,Bianca Ebtehadj,Pauline Ganley,John Hiscox,Catharina Hartman,Leia Kane,Stavroula Kastora,Sarah Lamb,Sinead McCarthy,Conal Mulholland,Imran Nadim,Jennifer Noble,Gareth Patton,David Savage,Benjamin Spowage-Delaney,Reece Doonan,Stephanie Lee,Joshua Strange,Ffion Barham,Clare Bosanko,Richard Bullough,Joan Danglosi,Elaine Freeman,Luci-Adele Jackson,Robert James,Louise Jose,Fionna Lowe,Ashleigh Lowther,Ian McCarthy,David McConnell,Richard Parry,Henry Shirreff,Jason Smith,Rosalyn Squire,Wayne Battishill,Girish Boggaram,Gemma Chilcott,James Gagg,Emma Machin,Charmaine Shovelton,Rebecca Purnell,Richard Crosthwaite-Eyre,George Page,Andrew Pitt,Peter Riou,Daisy Sykes,Cassie Worth,Lily Zitter,Tanya Baron,Dineshbabu Baskaran,Sally Beer,Akshay Bhargav,Helen Blamey,Charlotte Brown,Benjamin Clare-Gray,Matthew Davies,Neil Dawson,Karen Dineen,Iain Edgar,Vishakha Erasu,Muhammad Faisal,Dominique Georgiou,Alice Gibson,Rashpal Ghataoura,Samuel Glover,Olivia Gordon,Sadaf Ilyas,Aimee Jeffs,Henry Knott,Sneha Kundoor,Jose Martinez,Andrew McCallum,Alex Novak,Tine Panduro,Ravi Pattanshetty,Immanuel Paul,Rufino Roger Magallano,Pamposh Razdan,Tinelly Sambo,Sumaiyah Shah,Ayisha Shaikh,Simon Smith,Hannah Thraves,Charlotte Tickle,Justin Ang,Adrian Boyle,Susie Hardwick,Kerry Meynell,Samuel Miller,Julia Charsley,Sarah Jolly,Faye Mahony,Jade Moseley-Rodgers,Narani Sivayoham,Thomas Sheerin,Claire Seel,Mohamed Abdalla,Gregor Cameron,James Harnett,Daryl Ramos,Fabiola Sevilla Perez,Rachel White,Wajiha Abdullah,Suzanna Ballard,Katie Barnes,Rebecca Clegg,Elisha Cousins,Simon Cumiskey,Bashar Elwir,Alexander Ferriman,Alison Fletcher,Charlotte Griffiths,Paolyn Guiling,Graham Johnson,Benjamin Loach,Alison Matthews,Lucy May-Moulden,Rebecca Norman,Helen Seelly,Richard Smith,Andrew Tabner,Nicholas Tilbury,Thomas Ward,Lianne Wright,Heather Wroblewski,Marcelina Zawadzka
DOI: https://doi.org/10.1097/CCM.0000000000006348
2024-10-01
Abstract:Objectives: International guidelines recommend IV crystalloid as the primary fluid for sepsis resuscitation, with 5% human albumin solution (HAS) as the second line. However, it is unclear which fluid has superior clinical effectiveness. We conducted a trial to assess the feasibility of delivering a randomized controlled trial comparing balanced crystalloid against 5% HAS as sole early resuscitation fluid in patients with sepsis presenting to hospital. Design: Multicenter, open, parallel-group randomized feasibility trial. Setting: Emergency departments (EDs) in 15 U.K. National Health Service (NHS) hospitals. Patients: Adult patients with sepsis and a National Early Warning Score 2 greater than or equal to five requiring IV fluids withing one hour of randomization. Interventions: IV fluid resuscitation with balanced crystalloid or 5% HAS for the first 6 hours following randomization. Measurements and main results: Primary feasibility outcomes were recruitment rate and 30-day mortality. We successfully recruited 301 participants over 12 months. Mean ( sd ) age was 69 years (± 16 yr), and 151 (50%) were male. From 1303 participants screened; 502 participants were potentially eligible and 300 randomized to receive trial intervention with greater than 95% of participants receiving the intervention. The median number of participants per site was 19 (range, 1-63). Thirty-day mortality was 17.9% ( n = 53). Thirty-one participants died (21.1%) within 30 days in the 5% HAS arm, compared with 22 participants (14.8%) in the crystalloid arm (adjusted odds ratio, 1.50; 95% CIs, 0.84-2.83). Conclusions: Our results suggest it is feasible to recruit critically ill patients to a fluid resuscitation trial in U.K. EDs using 5% HAS as a primary resuscitation fluid. There was lower mortality in the balanced crystalloid arm. Given these findings, a definitive trial is likely to be deliverable, but the point estimates suggest such a trial would be unlikely to demonstrate a significant benefit from using 5% HAS as a primary resuscitation fluid in sepsis.